{"id":55174,"date":"2026-01-22T21:03:59","date_gmt":"2026-01-22T13:03:59","guid":{"rendered":"https:\/\/flcube.com\/?p=55174"},"modified":"2026-01-22T21:04:00","modified_gmt":"2026-01-22T13:04:00","slug":"huadong-medicine-secures-exclusive-china-commercialization-rights-for-linaprazan-glurate-p-cab-from-sinorda","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55174","title":{"rendered":"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization partnership with <strong>Guizhou Sinorda Biotechnology Co., Ltd.<\/strong> for <strong>Linaprazan glurate<\/strong>, a next\u2011generation potassium\u2011competitive acid blocker (P\u2011CAB) for gastrointestinal diseases in Mainland China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-responsibilities\">Deal Structure &amp; Responsibilities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Huadong Medicine (commercialization) \/ Sinorda (MAH)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (exclusive)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Linaprazan glurate capsules<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Erosive esophagitis (reflux esophagitis) and other GI acid\u2011related disorders<\/td><\/tr><tr><td><strong>Deal Type<\/strong><\/td><td>Exclusive commercialization agreement<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + undisclosed milestone payments (specifics not disclosed)<\/td><\/tr><tr><td><strong>Approval Status<\/strong><\/td><td>Approved in China; included in 2025 National Reimbursement Drug List (NRDL)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-strategic-positioning\">Drug Profile &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Next\u2011generation <strong>Potassium\u2011Competitive Acid Blocker (P\u2011CAB)<\/strong> that provides rapid, potent, and durable gastric acid suppression compared to traditional proton\u2011pump inhibitors (PPIs).<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Co\u2011developed by <strong>Sinorda<\/strong> and <strong>Cinclus Pharma<\/strong>; Sinorda holds global IP and serves as Marketing Authorization Holder (MAH).<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Inclusion in the <strong>2025 NRDL<\/strong> ensures reimbursement coverage, accelerating hospital listing and patient access across Tier\u20111 to Tier\u20113 cities.<\/li>\n\n\n\n<li><strong>Clinical Value:<\/strong> Demonstrates faster onset of action and improved nighttime acid control, addressing unmet needs in severe reflux disease.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China GI Market:<\/strong> The domestic market for acid\u2011suppression therapies exceeds <strong>\u00a58\u202fbillion<\/strong> (~US$1.1\u202fbillion) annually, with P\u2011CABs gaining share as hospitals seek alternatives to generic PPIs.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Huadong Medicine projects <strong>\u00a5300\u2013400\u202fmillion<\/strong> in first\u2011year sales (2026) for Linaprazan glurate, leveraging its 3,000\u2011person sales force and established relationships with 5,000+ hospitals.<\/li>\n\n\n\n<li><strong>Strategic Synergy:<\/strong> This partnership strengthens Huadong\u2019s gastroenterology portfolio, complementing its existing franchise in immunology and metabolic diseases.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Huadong will initiate a nationwide marketing campaign in Q1\u202f2026, targeting both gastroenterology KOLs and primary\u2011care physicians in high\u2011prevalence regions.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief includes forward\u2011looking statements regarding commercial expectations, revenue forecasts, and market penetration for Linaprazan glurate. Actual results may differ materially due to regulatory changes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[622,114,887,2629],"class_list":["post-55174","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gastroenterology","tag-huadong-medicine","tag-she-000963","tag-sinorda-biomedicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization partnership with Guizhou Sinorda Biotechnology Co., Ltd. for Linaprazan glurate, a next\u2011generation potassium\u2011competitive acid blocker (P\u2011CAB) for gastrointestinal diseases in Mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55174\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization partnership with Guizhou Sinorda Biotechnology Co., Ltd. for Linaprazan glurate, a next\u2011generation potassium\u2011competitive acid blocker (P\u2011CAB) for gastrointestinal diseases in Mainland China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55174\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T13:03:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T13:04:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55174#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55174\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda\",\"datePublished\":\"2026-01-22T13:03:59+00:00\",\"dateModified\":\"2026-01-22T13:04:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55174\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gastroenterology\",\"Huadong Medicine\",\"SHE: 000963\",\"Sinorda Biomedicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55174#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55174\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55174\",\"name\":\"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T13:03:59+00:00\",\"dateModified\":\"2026-01-22T13:04:00+00:00\",\"description\":\"Huadong Medicine Co., Ltd. (SHE: 000963), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization partnership with Guizhou Sinorda Biotechnology Co., Ltd. for Linaprazan glurate, a next\u2011generation potassium\u2011competitive acid blocker (P\u2011CAB) for gastrointestinal diseases in Mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55174#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55174\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55174#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd. (SHE: 000963), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization partnership with Guizhou Sinorda Biotechnology Co., Ltd. for Linaprazan glurate, a next\u2011generation potassium\u2011competitive acid blocker (P\u2011CAB) for gastrointestinal diseases in Mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55174","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda","og_description":"Huadong Medicine Co., Ltd. (SHE: 000963), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization partnership with Guizhou Sinorda Biotechnology Co., Ltd. for Linaprazan glurate, a next\u2011generation potassium\u2011competitive acid blocker (P\u2011CAB) for gastrointestinal diseases in Mainland China.","og_url":"https:\/\/flcube.com\/?p=55174","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T13:03:59+00:00","article_modified_time":"2026-01-22T13:04:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55174#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55174"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda","datePublished":"2026-01-22T13:03:59+00:00","dateModified":"2026-01-22T13:04:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55174"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gastroenterology","Huadong Medicine","SHE: 000963","Sinorda Biomedicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55174#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55174","url":"https:\/\/flcube.com\/?p=55174","name":"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T13:03:59+00:00","dateModified":"2026-01-22T13:04:00+00:00","description":"Huadong Medicine Co., Ltd. (SHE: 000963), a leading China\u2011based pharmaceutical group, announced an exclusive commercialization partnership with Guizhou Sinorda Biotechnology Co., Ltd. for Linaprazan glurate, a next\u2011generation potassium\u2011competitive acid blocker (P\u2011CAB) for gastrointestinal diseases in Mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55174#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55174"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55174#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P\u2011CAB from Sinorda"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55174"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55174\/revisions"}],"predecessor-version":[{"id":55175,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55174\/revisions\/55175"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}